Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS).Investigate the effect of CDP323, an oral α4-integrin inhibitor, on lymphocyte biomarkers in RMS.Seventy-one RMS subjects aged 18-65 years with Expanded Disability Status Sc...
Main Authors: | Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L Morris, Jennifer Cnops, Jorg Taubel, Barbara Bennett |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3589412?pdf=render |
Similar Items
-
VLA Scholarship Winners
by: Sandra Shell
Published: (2005-10-01) -
2004 VLA Conference
by: Editorial Team
Published: (2005-04-01) -
2005 VLA Conference
by: Editorial Team
Published: (2006-04-01) -
VLA Awards: An Overview
by: Lisa Lee Broughman, et al.
Published: (2011-08-01) -
VLA Conference Exhibitors
by: Editorial Team
Published: (2002-04-01)